Seeking Alpha

Seeking Alpha Portfolio App for iPad

LATEST ARTICLES

ARTICLES | NEWS | TRANSCRIPTS

Will Arena's Belviq Be The Next Anti-Obesity Drug To Make The Cover Of Time Magazine?
Reasonable Risk • VVUS, ESALY.PK, ARNA • Thu, May 23, 02:49 ET
Why Doctors Can Prescribe Arena's Belviq For Off Label Uses Without Worrying About Legal Liability
Jacob Smith • ARNA • Wed, May 22, 23:06 ET
Regeneron Shareholders Watching Optina Trial Closely
Tom Welch • AMPE, NVS, REGN • Wed, May 22, 15:56 ET
Sequenom: Plenty Of Room To Run
Ravi Jain • SQNM • Wed, May 22, 15:54 ET
Ariad's Cancer Drug Iclusig Extends The Gleevec Magic
Peter Geschek • NVS, ARIA • Wed, May 22, 13:20 ET
Why Momenta Offers A Unique Opportunity In The Pharmaceutical Industry
Jon Crowley • BAX, NVS, TEVA • Wed, May 22, 12:56 ET
Dendreon Analysts Getting Very Skeptical
Bill Maurer • DNDN • Wed, May 22, 08:49 ET
The 'New' Celsion Could Be Worth $4 A Share
Quoth the Raven • CLSN • Wed, May 22, 08:28 ET
Neuralstem Phase I Results Encourage Market, Stimulate Buying
Brian L. Wilson • CUR • Wed, May 22, 07:33 ET
Hodgkin Lymphoma: The Top Secret Strategy Of Seattle Genetics Revealed
Michael Webb • SGEN • Wed, May 22, 06:02 ET
Pricing A Highly Probable Takeover Of MannKind
George Rho • LLY, MRK, NVO • Wed, May 22, 05:28 ET
Arena Pharmaceuticals - Out To Launch Or Out To Lunch?
Spencer Osborne • VVUS, ARNA • Wed, May 22, 03:19 ET
Synergy Is A Straightforward Opportunity: Trial Results At DDW Back Plecanatide
PropThink • IRWD, FRX, SCMP • Tue, May 21, 13:41 ET
A Game-Changing Cancer Screen For Exact Sciences
Biotech Vet • EXAS • Tue, May 21, 10:57 ET
Neuralstem: Update On Phase I Trial Of Neural Stem Cells In ALS Is Encouraging
Smith On Stocks • CUR • Tue, May 21, 08:18 ET
The Facebook Effect On Arena's Belviq Sales And Why It Will Ultimately Dwarf Anything Eisai Does
Jacob Smith • VVUS, ESALY.PK, ARNA • Tue, May 21, 06:56 ET
A Focus On Stem-Cell Therapy And Regenerative Medicine For 2013
A John Hodge • PSTI, CUR, CYTX • Mon, May 20, 11:38 ET
Arena NOLs Will Come Into Play Soon
Spencer Osborne • LMCA, SIRI, ARNA • Mon, May 20, 03:05 ET
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • BMY, MNKD, MRK • Sun, May 19, 16:43 ET
Benjamin Graham's Rules For The Common Stock Component: Questcor Pharmaceuticals Inc.
Jarrod W. Jacinth • QCOR • Sun, May 19, 11:35 ET
Vivus Taps Into More Cash
Spencer Osborne • ARNA, VVUS • Sun, May 19, 09:41 ET
Why MannKind's Afrezza Will Succeed Where Pfizer Failed
Cory Renauer • NVO, PFE, MNKD • Sat, May 18, 04:45 ET
Here's Why Amgen Shares Are Worth $117 To $126 Today
Stephen Barnes • AMGN • Sat, May 18, 01:03 ET
Oncothyreon A Speculative Buy
Northwest Trader • BMY, MKGAY.PK, MRK • Fri, May 17, 20:52 ET
Arena Outlines Belviq Launch And Goals
Spencer Osborne • ARNA, ESALY.PK • Fri, May 17, 02:01 ET
Why You Should Be Investing In DNA Vaccination Technology And Inovio Pharmaceuticals
Healthcare Specialist • INO • Thu, May 16, 11:38 ET
Neuralstem: Update On ALS Trial Could Be A Catalyst For The Stock
Smith On Stocks • CUR • Thu, May 16, 09:55 ET
Neuralstem Rounding Second With Phase II ALS Trial
Ryan's View • CUR • Thu, May 16, 07:56 ET
A Breakdown Of Advanced Cell Technology's Latest Conference Call
Michael J. Ray • ACTC.OB • Thu, May 16, 01:26 ET
Amicus Therapeutics: The Good And The Bad
Biomed Group • GSK, FOLD • Wed, May 15, 13:31 ET
Galena Targets Cancer Pain Market
Len Zehr • GALE • Wed, May 15, 12:19 ET
Vivus - Mild Drama Continues
Spencer Osborne • ARNA, VVUS • Wed, May 15, 10:18 ET
2 BioPharma Catalyst Trades And 1 Strong Acquisition Target Rumored To Be In Play
Scott Matusow • ACAD, INSM, SRPT • Wed, May 15, 08:31 ET
Biosensors Expands Its Horizons With Imaging Buy
EP Vantage • BSNRF.PK • Tue, May 14, 17:51 ET
Once Heralded Dendreon May Be Approaching The End Of Its Financial Road
Amy Baldwin • DNDN • Tue, May 14, 16:15 ET
Celgene: Apremilast For Psoriatic Arthritis Offers Upside
Todd Campbell • ABBV, AMGN, JNJ • Tue, May 14, 12:50 ET
Significant Near-Term Top-Line Data Catalyst And Platform Technology Should Propel Insmed
Scott Matusow • AEGR, CRTX, FOLD • Tue, May 14, 10:01 ET
Inovio Pharmaceuticals: Why Best Therapeutic Vaccine Award In 2013?
Iggy Igette • INO • Tue, May 14, 07:15 ET
Arena, Vivus, And Off-Label Prescriptions
Spencer Osborne • VVUS, ARNA • Tue, May 14, 01:08 ET
Galena Biopharma: Stock First, Science Second?
Avi Greenberg • GALE • Mon, May 13, 14:01 ET
Is Regeneron A Value Pick In The Pharma Sector?
Emerging Equities • PFE, AMGN, SNY • Mon, May 13, 11:24 ET
OvaScience: Quietly Changing The Standard In Infertility Treatment
Healthcare Specialist • OVAS • Mon, May 13, 08:41 ET
Belviq's Sales Will Disappoint: Demographics Matter
EnhydrisPECorp • VVUS, ARNA • Fri, May 10, 14:31 ET
A Look At Neurocrine's VMAT-2 Inhibitor As Phase IIb Data Nears
Jason Napodano • ABBV, NBIX • Fri, May 10, 13:37 ET
Achillion: Down But Not Out And Progress Being Made
Regarded Solutions • BMY, ACHN • Fri, May 10, 13:22 ET
Bear Of The Day: Techne Corp.
Zacks Investment Research • TECH • Fri, May 10, 08:24 ET
Upcoming Catalysts Could Push ChemoCentryx To Double In 2013
BPD Research • GSK, CCXI • Fri, May 10, 04:00 ET
Is Dendreon Done After Q1 Train Wreck?
Bill Maurer • JNJ, MDVN, DNDN • Fri, May 10, 02:20 ET
Vivus Shifting Gears
Spencer Osborne • ARNA, VVUS • Fri, May 10, 02:07 ET
For Arena, Sales Is Key
Spencer Osborne • ARNA • Fri, May 10, 00:21 ET

First Page
Previous Page
1 - 50 of 4250
Next Page
Last Page